Outcomes of Conversion from Valganciclovir to Letermovir for Cytomegalovirus Prophylaxis in Abdominal Transplant Recipients (ATC 2026) - Jun 17, 2026 - Abstract #Abstract B375; Pres time: Jun 21, 2026; 02:45 PM - 03:45 PM; Location: Exhibit Hall; "Overall, patients converted to LET for CMV prophylaxis had an increase in median WBC, less GCSF use, and an increase in antimetabolite dosing. This supports use of LET conversion in leukopenic abdominal transplant patients, allowing for optimization of immunosuppression."
Clinical • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Leukopenia • Transplantation
|
|
L. McCord 1; E. Graves 1; B. Summers 1; A. Gerlach 1; T. Pesavento 2; N. Marschalk 1; A. Nolan 1
|